Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. trimmed its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 3.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,941 shares of the company’s stock after selling 6,156 shares during the quarter. Vontobel Holding Ltd. owned 0.08% of Autolus Therapeutics worth $729,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AUTL. Avoro Capital Advisors LLC acquired a new position in Autolus Therapeutics during the first quarter worth about $78,765,000. Armistice Capital LLC lifted its holdings in shares of Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after purchasing an additional 1,578,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after purchasing an additional 2,487,778 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Autolus Therapeutics by 27.4% in the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares in the last quarter. Finally, Great Point Partners LLC lifted its stake in shares of Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after buying an additional 2,275,000 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $4.80 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.00 and a beta of 2.04. The company’s 50 day simple moving average is $3.94 and its 200 day simple moving average is $4.12. Autolus Therapeutics plc has a 1 year low of $2.21 and a 1 year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). On average, sell-side analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.